Abstract:Rationale: Resistance to androgen-deprivation therapy (ADT) associated with metastatic progression remains a challenging clinical task in prostate cancer (PCa) treatment. Current targeted therapies for castration-resistant prostate cancer (CRPC) are not durable. The exact molecular mechanisms mediating resistance to castration therapy that lead to CRPC progression remain obscure.Methods: The expression of MYB proto-oncogene like 2 (MYBL2) was evaluated in PCa samples. The effect of MYBL2 on the response to ADT was determined by in vitro and in vivo experiments. The survival of patients with PCa was analyzed using clinical specimens (n = 132) and data from The Cancer Genome Atlas (n = 450). The mechanistic model of MYBL2 in regulating gene expression was further detected by subcellular fractionation, western blotting, quantitative real-time PCR, chromatin immunoprecipitation, and luciferase reporter assays.Results: MYBL2 expression was significantly upregulated in CRPC tissues and cell lines. Overexpression of MYBL2 could facilitate castration-resistant growth and metastatic capacity in androgen-dependent PCa cells by promoting YAP1 transcriptional activity via modulating the activity of the Rho GTPases RhoA and LATS1 kinase. Importantly, targeting MYBL2, or treatment with either the YAP/TAZ inhibitor Verteporfin or the RhoA inhibitor Simvastatin, reversed the resistance to ADT and blocked bone metastasis in CRPC cells. Finally, high MYBL2 levels were positively associated with TNM stage, total PSA level, and Gleason score and predicted a higher risk of metastatic relapse and poor prognosis in patients with PCa.Conclusions: Our results reveal a novel molecular mechanism conferring resistance to ADT and provide a strong rationale for potential therapeutic strategies against CRPC.

MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3

Overexpression of MYBL2 Promotes Proliferation and Migration of Non-Small-cell Lung Cancer Via Upregulating NCAPH

MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer.

MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis

Prognostic Implications of MYBL2 in Resected Chinese Gastric Adenocarcinoma Patients

Mybl2 is A Potential Prognostic Marker That Promotes Cell Proliferation in Gallbladder Cancer

Downstream Regulatory Network of MYBL2 Mediating Its Oncogenic Role in Melanoma

LncRNA MBNL1-AS1 represses cell proliferation and enhances cell apoptosis via targeting miR-135a-5p/PHLPP2/FOXO1 axis in bladder cancer

M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription

DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC

Genome-wide binding analysis unveils critical implication of B-Myb-mediated transactivation in cancers

C-Myb Enhances Breast Cancer Invasion And Metastasis Through The Wnt/Beta-Catenin/Axin2 Pathway

Combinatorial transcriptional regulation of HEB/ZEB1/ASCL1 and MYBL2 on Ras/ErbB signaling

C-Myb Enhances Breast Cancer Invasion and Metastasis Through the Wnt/β-Catenin/Axin2 Pathway.

Long Noncoding RNA BLACAT2 Promotes Bladder Cancer–associated Lymphangiogenesis and Lymphatic Metastasis

DLGAP5 triggers proliferation and metastasis of bladder cancer by stabilizing E2F1 via USP11

MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer

Metadherin Promotes the Development of Bladder Cancer by Enhancing Cell Division

ACAT1 Promotes Proliferation and Metastasis of Bladder Cancer Via AKT/GSK3β/c-Myc Signaling Pathway

Dynamic Changes in Myofibroblasts Affect the Carcinogenesis and Prognosis of Bladder Cancer Associated With Tumor Microenvironment Remodeling

RRM2 Is a Putative Biomarker and Promotes Bladder Cancer Progression via PI3K/AKT/mTOR Pathway